Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Vincristine Variant #01 | — | R 9 687 | 70d | — | — | ~1 | ~R 9 687 indirect | — |
Temozolomide monotherapy Variant #02 | — | R 3 434 | 14d | 39.0 mo | — | 27 | R 92 712 PFS proxy | 1 |
PCV Variant #02 Partial | — | R 327 | 56d | — | 159.6 mo | 12 | R 3 919 PFS proxy | 1 |
Observation Partial | — | — | — | — | 93.6 mo | — | — | 1 |
Radiation therapy N/A - radiation | — | — | 49d | 46.0 mo | — | — | — | 1 |
5 of 5 regimens shown